Sharing our perspective

Sharing perspectives leads to greater understanding and fuels innovation. The ​Optum Insights ​blog is where we share our perspective and challenge preconceptions to clear a new path forward.


  • Pennsylvania Senate passes drug formulary

    by
    • Optum Workers' Comp
    | Oct 27, 2017
    Tag Icon
    Formularies
    The Pennsylvania Senate passed Senate Bill 936 (SB936) on October 25, 2017, with a vote of thirty-four to sixteen, moving the bill to the House for approval. The original version of the bill was passed with no amendments. The bill proposes the state’s Department of Labor and Industry select a nationally recognized, evidence-based prescription drug formulary appropriate for resolving issues related to drugs prescribed for or related to the treatment of work-related injuries.


  • California Division of Workers Compensation submits formulary regulations for final approval

    by
    • Optum Workers' Comp
    | Oct 26, 2017
    Tag Icon
    Formularies
    The Division of Workers Compensation (DWC) appears to have submitted what is expected to be the final version of its proposed formulary rules to the Office of Administrative Law (OAL) for final approval more than 60 days prior to the January 1, 2018 effective date.


  • Lyrica® CR (pregabalin extended-release) - New formulation approved

    by
    • Optum Workers' Comp
    | Oct 24, 2017
    Tag Icon
    Diabetes, FDA
    Pfizer Inc. recently announced the approval of Lyrica CR (pregabalin) extended-release tablets by the U.S. Food and Drug Administration (FDA). Lyrica CR has been approved for once-daily therapy for the treatment of neuropathic (nerve) pain associated with diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN), known as nerve pain caused by shingles.


  • Potential shortages of medical devices manufactured in Puerto Rico

    by
    | Oct 24, 2017
    Tag Icon
    FDA
    In the wake of Hurricanes Irma and Maria, the U.S. Food and Drug Administration (FDA) has become aware and is monitoring the supply of more than forty drug products, including medical devices, manufactured by facilities in Puerto Rico. As a result of the devastation, lack of power, connectivity, transportation, clean water, raw materials and supplies have all contributed to growing concerns around the potential for critical shortages of medications and medical devices produced in fifty facilities on the island.






Subscribe

Stay informed by signing up to receive newsletters, alerts, insights and videos.
You can customize your content preferences after you subscribe.